A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-04

Study Completion Date

2021-10-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study consists of 2 parts: Part A is to estimate the relative bioavailability of a single 200 mg dose of abrocitinib oral suspension (Test formulation) compared to the commercial abrocitinib tablet (200 mg) (Reference formulation). The effect of an acid-reducing agent on the pharmacokinetics of abrocitinib and its metabolites will also be evaluated by administering abrocitinib 200 mg commercial tablet with or without famotidine 40 mg, as an acid-reducing agent. Part B is to assess the taste and palatability of six different abrocitinib oral suspension formulations. Additionally, the safety and tolerability of abrocitinib tablet (in Part A) and abrocitinib oral suspension formulations (in Part B) will be assessed when given with or without famotidine 40 mg once daily.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

NCT06078202

Healthy Volunteers

WITHDRAWN PHASE1

A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers

NCT01802853

Healthy Volunteer

COMPLETED PHASE1

Bioavailability of ATI-1501 With Taste Test Sub Study

NCT03337126

Bioequivalence

COMPLETED PHASE1

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

NCT02170792

Healthy

COMPLETED PHASE1

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

NCT06916143

Healthy Participants

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1 randomized study in healthy participants to estimate the relative bioavailability of abrocitinib oral suspension (Test formulation) compared to commercial abrocitinib tablet (Reference formulation) under fasted condition. The effect of an acid-reducing agent on the pharmacokinetics of the commercial tablet formulation will be evaluated by administering abrocitinib 200 mg commercial tablet with famotidine 40 mg, as an acid-reducing agent. Assessment of taste and palatability of six different abrocitinib suspension formulations will also be performed. This study consists of 2 parts, as listed below:

Part A

Part A of the study will be an open label, randomized, single dose, crossover, 3-treatment, 6 sequence, 3-period design in healthy male and/or female adult participants (18-55 years). Healthy participants will be screened within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. Eligible participants will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, on Day 2 of Period 9 in Part B, after completing both Parts A and B of the study. In Part A, participants will be randomized to receive one of the following: a single 200 mg dose of abrocitinib commercial tablet (Treatment A), a single 200 mg dose of abrocitinib oral suspension formulation 1 (Treatment B), or famotidine (40 mg) administered 120 minutes before a single 200 mg dose of abrocitinib commercial tablet (Treatment C). All participants will be fasting for at least 10 hours before taking abrocitinib.

Part B

Part B will be a single-blind, randomized, 6-period, crossover study in healthy male and/or female adult participants (18-55 years). For any new healthy participants joining Part B only, screening will be performed within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. New participants enrolled in Part B only will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, which is Day 2 of Period 9. On Day 1 of each treatment period under fasted conditions, participants will receive a famotidine tablet (40 mg with 240 mL of room temperature water) administered 120 minutes before a single 200 mg dose of abrocitinib oral suspensions (Formulations 1 to 6) or administered a single 200 mg dose of abrocitinib oral suspension alone (Formulations 1 to 6), after a fast of at least 10 hours before abrocitinib administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Part A: open label / Part B: single-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: Abrocitinib Tablet

Group Type EXPERIMENTAL

Abrocitinib tablet

Intervention Type DRUG

Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.

Part A: Abrocitinib Suspension F1

Group Type EXPERIMENTAL

Abrocitinib Suspension F1

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

Part A: Abrocitinib Tablet + Famotidine

Group Type EXPERIMENTAL

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Part B: Abrocitinib Suspension F1

Group Type EXPERIMENTAL

Abrocitinib Suspension F1

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

Part B: Abrocitinib Suspension F2

Group Type EXPERIMENTAL

Abrocitinib Suspension F2

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

Part B: Abrocitinib Suspension F3

Group Type EXPERIMENTAL

Abrocitinib Suspension F3

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

Part B: Abrocitinib Suspension F4

Group Type EXPERIMENTAL

Abrocitinib Suspension F4

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

Part B: Abrocitinib Suspension F5

Group Type EXPERIMENTAL

Abrocitinib Suspension F5

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

Part B: Abrocitinib Suspension F6

Group Type EXPERIMENTAL

Abrocitinib Suspension F6

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

Part B: Abrocitinib Suspension F1 + Famotidine

Group Type EXPERIMENTAL

Abrocitinib Suspension F1

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Part B: Abrocitinib Suspension F2 + Famotidine

Group Type EXPERIMENTAL

Abrocitinib Suspension F2

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Part B: Abrocitinib Suspension F3 + Famotidine

Group Type EXPERIMENTAL

Abrocitinib Suspension F3

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Part B: Abrocitinib Suspension F4 + Famotidine

Group Type EXPERIMENTAL

Abrocitinib Suspension F4

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Part B: Abrocitinib Suspension F5 + Famotidine

Group Type EXPERIMENTAL

Abrocitinib Suspension F5

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Part B: Abrocitinib Suspension F6 + Famotidine

Group Type EXPERIMENTAL

Abrocitinib Suspension F6

Intervention Type DRUG

Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

Famotidine

Intervention Type DRUG

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abrocitinib tablet

Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Abrocitinib Suspension F1

Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Abrocitinib Suspension F2

Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Abrocitinib Suspension F3

Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Abrocitinib Suspension F4

Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Abrocitinib Suspension F5

Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Abrocitinib Suspension F6

Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

Intervention Type DRUG

Famotidine

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, complete physical examination, laboratory tests, and cardiovascular tests.
* Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
* Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).
* Capable of giving signed informed consent.

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* History of human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C virus antibody (HCVAb).
* Other acute or chronic medical or psychiatric condition including recent (within the past year).

Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) or visible rash present during physical examination.

* Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product.
* A positive urine drug test.
* Selected laboratory abnormalities.
* History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
* History of tuberculosis (TB) (active or latent).
* Any history of chronic infections, any history of recurrent infections, any history of latent infections, or any acute infection within 2 weeks of baseline.
* Pregnant female participants; breastfeeding female participants; female participants of childbearing potential who are unwilling or unable to use an acceptable method of contraception.
* History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes